|
Medtronic Buys CathWorks, Top 50 Cardio-Hospitals, and AI Clearances
February 5, 2026
|
|
|
|
|
Together with
|
|
|
|
“Women in medicine: Earn less. Are less likely to be in leadership. Spend more hours on household responsibilities. Yet, they spend more time with patients and provide better care.”
|
|
Dimitrios Tsatiris, MD
|
|
|
|
Using AI algorithms to diagnose and assess coronary artery disease for intervention is about to become more mainstream after medtech giant, Medtronic, agreed to exercise its acquisition rights on AI FFR specialist, CathWorks, for $585M up-front.
- Although effective, traditional wire-based FFR measurement is invasive, requires more time, more radiation exposure, and higher costs, limiting its adoption.
- CathWorks’ FFRangio technology solves this problem by using algorithms to obtain FFR measurements across the coronary artery tree from standard angiograms.
Until now CathWorks’ FFRangio has only been available in the U.S., Europe, and Japan through Medtronic’s distribution network, but this expansion will take the tech global, with Medtronic’s full backing.
This strategic acquisition stems from Medtronic’s staged investment in CathWorks, which started with a $75M minority stake in 2022 and is now part of the company’s broader plan to expand its presence in the cath lab.
- Medtronic entered the stent business in 1998 with its acquisition of Arterial Vascular Engineering for about $3.7B.
- Since then, the company has improved and developed its own internal stent tech, with the Resolute Onyx and newer Onyx Frontier drug eluting stents.
- These products are engineered for treating coronary artery disease via PCI and go hand-in-hand with CathWorks’ diagnostic system.
The move is reminiscent of Philips’ SpectraWAVE acquisition in December 2025, which saw a similar on-boarding of wire-free FFR tech, signaling that the big players see the value in non-invasive CAD evaluation and planning.
- That acquisition stemmed from Philip’s cath lab focused expansion, though its approach is more imaging centered than interventional.
- Meanwhile, with Medtronic’s stent portfolio, integrating FFRangio could accelerate the technology’s adoption through established customers.
Medtronic might have also already laid the groundwork for two potentially similar acquisitions with its recent investing agreements, both in the interventional cardiology space.
- One is an exclusive U.S. distribution agreement with Contego Medical in January 2025, which started with increased investment ($22.3M) and comes with acquisition rights.
- The other is Medtronic’s $90M investment in Anteris Technologies (16% stake), though Medtronic can’t increase this stake till May 2027.
The Takeaway
Medtronic has consistently shown a “try-before-you-buy” approach when it comes to expanding its cardiology portfolio, and its latest purchase of CathWorks is no different. That’s a strategy that kept Medtronic safe while giving CathWorks’ FFRangio the room to grow into a global technology that could redefine PCI planning.
|
|
Heartflow Roadmap Analysis For Efficient Care
As Coronary CT scan volumes increase, your entire reading team needs to deliver efficient and consistent reads. Good thing Heartflow’s Roadmap Analysis can help you maintain accuracy and increase CCTA read speeds by up to 25%, with even level 3 readers seeing real efficiency benefits.
|
|
A Solution for Your Entire Cardiology Service Line
The pace of change in healthcare can be dizzying, creating new and more complex challenges for cardiology departments to overcome. See how Merge Cardio and Merge Hemo can turn those challenges into opportunities for greater workflow efficiency and improved care.
|
|
Making the Leap to Outsource Post-Processing
Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
|
|
- HeartLung Added to Microsoft’s PIN: AI solutions from HeartLung.AI will be added to Microsoft’s Precision Imaging Network AI orchestration platform under a new agreement between the companies. HeartLung’s AutoChamber algorithm for analyzing cardiac chamber structure and AutoBMD for calculating bone density will be made available to PIN users. Both solutions analyze CT images acquired for other indications to enable clinicians to opportunistically screen for pathology.
- eMurmur’s Heart AI Clearance: eMurmur received FDA 510(k) clearance for its hardware-agnostic auscultation platform, eMurmur Heart AI. The suite automatically identifies primary heart sounds (S1/S2) and detects both the presence and absence of murmurs with 90% sensitivity and specificity. Beyond screening, the software also provides hemodynamic data by calculating heart sound energy across systolic and diastolic phases. Designed for high-volume settings and virtual care, the open platform integrates with any supported digital stethoscope to provide cardiologist-level insights during routine exams.
- Joint Commission’s Outcomes-Based Certification: The Joint Commission partnered with the ACC and STS to announce a new cardiac care certification at STS 2026. This next-generation program shifts focus from process to real-world outcomes by leveraging existing data from the STS Adult Cardiac Surgery Database, ACC CathPCI Registry, and STS/ACC TVT Registry. By using established data streams, the certification aims to reduce administrative burden while allowing health systems to quantify clinical excellence and patient safety.
- GEHC Launches Allia Moveo: GE HealthCare received FDA clearance and CE Marking for Allia Moveo, a mobile, AI-powered interventional imaging platform that assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and surgical procedures. Following its first global installation in France and a U.S. debut at Baylor St. Luke’s, the system utilizes AI-driven tools like CleaRecon DL to improve image quality and reduce artifacts. Its compact, cable-free design and enhanced maneuverability aim to streamline workflows in space-constrained interventional and surgical suites.
- The 2026 Heart Health Matters Report: A survey of 400 benefit leaders by Hello Heart reveals a gap between cardiovascular cost awareness and prevention efforts. While 90% identify heart disease as a top cost driver, only 32% feel prepared for rising claims. Indirect costs from lost productivity are believed to exceed direct medical spend, while digital tools and improved medication adherence are seen as critical levers for lowering costs.
- The Top 50 Hospital CV Programs: Premier announced findings from the Top 50 Cardiovascular Hospital programs assessed on their performance across acute MI, HF, CABG, and PCI. Top performers on the list showed 56% better CABG mortality rates and 19.6% lower average costs per heart failure case compared to peer hospitals. The analysis also estimated that if all U.S. hospitals matched top performers’ cardiovascular outcomes, over 14,000 additional lives could be saved, 27,000 fewer procedure complications would occur, and $2B in potential savings could be realized.
- 1st ASC AFib Ablation in New Mexico: Current Clinic completed the first cardiac ablation procedures at its Carlsbad, New Mexico location, marking the state’s first cardiac ablations performed in an ambulatory surgery center (BSCI’s FARAPULSE PFA was used). Current Clinic is the nation’s first healthcare network focused on cardiac arrhythmia care, offering diagnosis through advanced procedures in cost-effective ambulatory settings. The company plans national expansion to bring specialized arrhythmia care to underserved communities, eliminating long-distance travel for treatment.
- SonoVascular’s Series A: SonoVascular closed a $6M Series A financing to advance its SonoThrombectomy System for venous thromboembolism. The ultrasound-facilitated system achieved 100% clot reduction in all 10 patients in its First-In-Human DVT study with no adverse events and sustained clinical improvements at six months. SonoThrombectomy uses microbubble-mediated cavitation combined with low-dose thrombolytic therapy to break down clots without blood loss or vascular trauma. Funding will support FDA approval for a U.S. pivotal study and a First-In-Human pulmonary embolism trial in 2026.
- INFINITT’s Best in KLAS Cardiology Win: INFINITT North America’s Cardiology Suite earned the top spot for performance and partnership in the 2026 Best in KLAS Awards. The web-based platform was recognized for its ability to unify complex workflows (including echo, cath, and nuclear medicine) into a single interface. Key drivers for the #1 ranking included its automated structured reporting, seamless EHR integration, and simplified data submission to critical registries like the STS and NCDR.
- Merge Hemo’s 2026 KLAS Win: Merative’s Merge Hemo earned the 2026 Best in KLAS award for cardiology hemodynamics, marking its 14th year as a category leader. The updated 11.2 version of Merge Hemo improves cath lab efficiency with Windows 11 compatibility and streamlined IT deployments. Additionally, Merge Cardio 12.5 ranked in the top three for cardiology monitoring solutions, introducing AI-generated echocardiogram measurements and new integrations with echo AI company, Us2.ai, to enhance clinical reporting confidence.
- Chamber Cardio’s $60M Series A: Chamber Cardio raised $60M to scale its value-based care platform, which integrates workflow-native AI into cardiologist EHRs. The startup aims to shift cardiology from fee-for-service to outcomes-driven models by providing automated risk stratification and administrative support. Early trial data shows that Chamber’s model reduced CHF-related hospitalizations by 39% and total inpatient admissions by 21%, offering payors and providers a management solution for high-cost CV patients.
|
|
Merge & Us2.ai for Accessible Cardiac AI
AI isn’t the future anymore, it’s an irreplaceable feature for cardiac imaging. Dive deeper into how Merge & Us2.ai are integrating FDA-cleared algorithms with advanced imaging systems to help clinicians focus on what matters most – their patients.
|
|
AHA Scientific Sessions Discussion: Heart Failure Treatment Developments and Impact on Women
Women with heart failure with preserved and mildly reduced ejection fraction (HFpEF and HFmrEF, respectively) often present with different symptoms than men, leading to underrecognition. Moreover, the incidence of HFpEF in women is increasing more than in men. Watch Dr. Martha Gulati discuss prevalence and changing treatment options.
|
|
Siemens Healthineers ACUSON Origin Ultrasound System is Redefining CVUS
ACUSON Origin meets the demands of today’s cardiovascular care with AI-powered efficiency across adult and pediatric echo, vascular, structural heart, and EP. Streamlined workflows, intuitive walk-up usability, and advanced ergonomics empower clinicians to deliver confident, high-quality care—supporting a wide range of complex cases and clinical applications.
|
|
- Earlier Detection, Better Outcomes: When it comes to heart disease, early detection is crucial to a patient’s long-term health. Learn more about how Fujifilm helps clinicians achieve that with the Lisendo 880 cardiovascular ultrasound system that detects early abnormalities while offering 3D/4D visualization of cardiac functions, heart failure, and hemodynamic analysis.
- Assessing CAD with Circle CVI: Did you know that Circle CVI offers a suite of cardiac CT tools for the assessment of coronary artery disease? See how Circle combines heart function segmentation, automated plaque analysis, CAC scoring, reporting, and viewing in a single dedicated Cardiac CT package.
- Vista AI Grows CMR Volume: Are your patients waiting weeks or months for cardiac MRIs? See Brigham and Women’s Hospital’s real-world results showing how Vista AI’s software for automated MRI scanning led to 50% more scan slots, without adding more scanners or staff.
- Precision QRS Detection: QRS detection is essential for any ECG algorithm, and Monebo’s Kinetic QRS ECG Algorithm sets the standard for accuracy. Kinetic QRS accurately detects the QRS complex, no matter the amplitude, waveform, or noise levels.
- Identify and Treat Cardiovascular Disease: Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.
|
|
|
|
|
